{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:06:44Z","timestamp":1779318404202,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Diabetes mellitus kann zu unterschiedlichen Augenerkrankungen f\u00fchren wie diabetische Retinopathie, diabetisches Makula\u00f6dem, Optikusneuropathie, Katarakt, Sekund\u00e4rglaukom und Fehlfunktionen der \u00e4u\u00dferen Augenmuskeln. Die Inzidenz dieser Sp\u00e4tsch\u00e4den korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Regul\u00e4re augenfach\u00e4rztliche Kontrollen sind notwendig, um visusbedrohende Sp\u00e4tsch\u00e4den einer diabetischen Augenerkrankung fr\u00fchzeitig zu erkennen und entsprechende Therapien einzuleiten.<\/jats:p>","DOI":"10.1007\/s00508-025-02691-8","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:51Z","timestamp":1779315411000},"page":"228-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostik, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung (Update 2026)","Diagnostics, treatment and monitoring of diabetic eye disease (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Andreas","family":"Pollreisz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Gasser-Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Gerendas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mennel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Radda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Stolba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Wedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2691_CR1","doi-asserted-by":"publisher","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","volume":"132","author":"JI Lim","year":"2025","unstructured":"Lim\u00a0JI, et\u00a0al. Diabetic retinopathy preferred practice pattern(R). Ophthalmology. 2025;132:P75\u2013P162.","journal-title":"Ophthalmology"},{"key":"2691_CR2","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1055\/a-1946-3798","volume":"131","author":"HP Hammes","year":"2023","unstructured":"Hammes\u00a0HP, Lemmen\u00a0KD, Bertram\u00a0B. Diabetic retinopathy and maculopathy. Exp Clin Endocrinol Diabetes. 2023;131:P66\u2013P71.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2691_CR3","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"SD Solomon","year":"2020","unstructured":"Solomon\u00a0SD, CJ. Diabetic retinopathy preferred practice pattern(R). Ophthalmology. 2020;127:P66\u2013P145.","journal-title":"Ophthalmology"},{"key":"2691_CR4","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1055\/a-1284-6223","volume":"129","author":"HP Hammes","year":"2021","unstructured":"Hammes\u00a0HP, Lemmen\u00a0KD, Bertram\u00a0B. Diabetic retinopathy and maculopathy. Exp Clin Endocrinol Diabetes. 2021;129:S64\u2013S9.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2691_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc16-2641","volume":"40","author":"SD Solomon","year":"2017","unstructured":"Solomon\u00a0SD, et\u00a0al. Diabetic retinopathy: a\u00a0position statement by the American diabetes association. Diabetes Care. 2017;40:412\u20138.","journal-title":"Diabetes Care"},{"key":"2691_CR6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2337\/diacare.15.12.1875","volume":"15","author":"R Klein","year":"1992","unstructured":"Klein\u00a0R, Klein\u00a0BE, Moss\u00a0SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875\u201391.","journal-title":"Diabetes Care"},{"issue":"41","key":"2691_CR7","first-page":"255","volume":"2020","author":"F Cosentino","year":"2019","unstructured":"Cosentino\u00a0F, et\u00a0al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart\u00a0J. 2019;2020(41):255\u2013323.","journal-title":"Eur Heart J"},{"key":"2691_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2337\/diacare.24.7.1275","volume":"24","author":"L Zhang","year":"2001","unstructured":"Zhang\u00a0L, Krzentowski\u00a0G, Albert\u00a0A, Lefebvre\u00a0PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275\u20139.","journal-title":"Diabetes Care"},{"key":"2691_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","volume":"44","author":"IM Stratton","year":"2001","unstructured":"Stratton\u00a0IM, et\u00a0al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156\u201363.","journal-title":"Diabetologia"},{"key":"2691_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/archopht.1990.01070040067032","volume":"108","author":"RP Murphy","year":"1990","unstructured":"Murphy\u00a0RP, et\u00a0al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108:215\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2691_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","volume":"23","author":"C Diabetes","year":"2000","unstructured":"Diabetes\u00a0C, G. Complications Trial Research. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes\u00a0Control and Complications Trial Research Group. Diabetes\u00a0Care. 2000;23:1084\u201391.","journal-title":"Diabetes Care"},{"key":"2691_CR12","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archopht.116.7.874","volume":"116","author":"-","year":"1998","unstructured":"-. Anonymous, Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874\u201386.","journal-title":"Arch Ophthalmol"},{"key":"2691_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain\u00a0SC, Klufas\u00a0MA, Ho\u00a0A, Matthews\u00a0DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a\u00a0review. Diabetes Obes Metab. 2019;21:454\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"2691_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3949\/ccjm.66.4.247","volume":"66","author":"CE Nasr","year":"1999","unstructured":"Nasr\u00a0CE, Hoogwerf\u00a0BJ, Faiman\u00a0C, Reddy\u00a0SS, United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66:247\u201353.","journal-title":"Cleve Clin J Med"},{"key":"2691_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ophtha.2008.09.042","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz\u00a0M, et\u00a0al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116:66\u201372.","journal-title":"Ophthalmology"},{"issue":"1","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/biomedicines10010088","volume":"10","author":"A Boned-Murillo","year":"2021","unstructured":"Boned-Murillo\u00a0A, et\u00a0al. Optical coherence tomography angiography in diabetic patients: a\u00a0systematic review. Biomedicines. 2021;10(1):88.","journal-title":"Biomedicines"},{"key":"2691_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40942-020-00253-w","volume":"6","author":"D Hajdu","year":"2020","unstructured":"Hajdu\u00a0D, et\u00a0al. Association of macular perfusion status with microvascular parameters up to the far periphery in diabetic retinopathy using multimodal imaging. Int J Retin Vitreous. 2020;6:50.","journal-title":"Int J Retin Vitreous"},{"key":"2691_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","volume":"64","author":"RF Spaide","year":"2018","unstructured":"Spaide\u00a0RF, Fujimoto\u00a0JG, Waheed\u00a0NK, Sadda\u00a0SR, Staurenghi\u00a0G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1\u201355.","journal-title":"Prog Retin Eye Res"},{"key":"2691_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0161-6420(13)38015-4","volume":"98","author":"-","year":"1991","unstructured":"-. Anonymous, Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:834\u201340.","journal-title":"Ophthalmology"},{"key":"2691_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15110","author":"V Schreur","year":"2022","unstructured":"Schreur\u00a0V, et\u00a0al. Imaging diabetic retinal disease: clinical imaging requirements. Acta Ophthalmol. 2022; https:\/\/doi.org\/10.1111\/aos.15110.","journal-title":"Acta Ophthalmol"},{"key":"2691_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti\u00a0DA, Klein\u00a0R, Gardner\u00a0TW. Diabetic retinopathy. N\u00a0Engl J Med. 2012;366:1227\u201339.","journal-title":"N Engl J Med"},{"key":"2691_CR22","volume-title":"R. G. e. V. Deutsche Ophthalmologisce Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e. V. , Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makula\u00f6dems","author":"-","year":"2020","unstructured":"-. R. G. e. V. Deutsche Ophthalmologisce Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e. V. , Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makula\u00f6dems. 2020."},{"key":"2691_CR23","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong\u00a0TY, et\u00a0al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608\u201322.","journal-title":"Ophthalmology"},{"key":"2691_CR24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/NEJMra1909637","volume":"382","author":"LM Jampol","year":"2020","unstructured":"Jampol\u00a0LM, Glassman\u00a0AR, Sun\u00a0J. Evaluation and care of patients with diabetic retinopathy. N\u00a0Engl J Med. 2020;382:1629\u201337.","journal-title":"N Engl J Med"},{"key":"2691_CR25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1055\/a-1191-1395","volume":"237","author":"G Deutsche Ophthalmologische","year":"2020","unstructured":"Deutsche Ophthalmologische\u00a0G. Retinologische Gesellschaft e, V., Berufsverband der Augenarzte Deutschlands. Klin Monbl Augenheilkd. 2020;237:990\u20134.","journal-title":"Klin Monbl Augenheilkd"},{"key":"2691_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","volume":"139","author":"RK Maturi","year":"2021","unstructured":"Maturi\u00a0RK, et\u00a0al. Effect of intravitreous anti-vascular Endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol. 2021;139:701\u201312.","journal-title":"JAMA Ophthalmol"},{"key":"2691_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","volume":"136","author":"JG Gross","year":"2018","unstructured":"Gross\u00a0JG, et\u00a0al. Five-year outcomes of panretinal photocoagulation vs Intravitreous ranibizumab for proliferative diabetic retinopathy: a\u00a0randomized clinical trial. JAMA Ophthalmol. 2018;136:1138\u201348.","journal-title":"JAMA Ophthalmol"},{"key":"2691_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","volume":"126","author":"A Obeid","year":"2019","unstructured":"Obeid\u00a0A, et\u00a0al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular Endothelial growth factor. Ophthalmology. 2019;126:407\u201313.","journal-title":"Ophthalmology"},{"key":"2691_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman\u00a0AR, et\u00a0al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study). Ophthalmology. 2020;127:1201\u201310.","journal-title":"Ophthalmology"},{"key":"2691_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen\u00a0QD, et\u00a0al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"2691_CR31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"N. Diabetic Retinopathy Clinical Research","year":"2010","unstructured":"N. Diabetic Retinopathy Clinical Research, et\u00a0al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064\u20131077.e35.","journal-title":"Ophthalmology"},{"key":"2691_CR32","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik\u00a0JF, et\u00a0al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u201354.","journal-title":"Ophthalmology"},{"key":"2691_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown\u00a0DM, et\u00a0al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"key":"2691_CR34","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker\u00a0CW, et\u00a0al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a\u00a0randomized clinical trial. JAMA. 2019;321:1880\u201394.","journal-title":"JAMA"},{"key":"2691_CR35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff\u00a0CC, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"2691_CR36","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"-","year":"1985","unstructured":"-. Anonymous, Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796\u2013806.","journal-title":"Arch Ophthalmol"},{"key":"2691_CR37","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","volume":"324","author":"AN Antoszyk","year":"2020","unstructured":"Antoszyk\u00a0AN, et\u00a0al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic Retinopathy: a\u00a0randomized clinical trial. JAMA. 2020;324:2383\u201395.","journal-title":"JAMA"},{"key":"2691_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamaophthalmol.2021.1110","volume":"139","author":"AR Glassman","year":"2021","unstructured":"Glassman\u00a0AR, et\u00a0al. Visual acuity, vitreous hemorrhage, and other ocular outcomes after vitrectomy vs aflibercept for vitreous hemorrhage due to diabetic retinopathy: a\u00a0secondary analysis of a\u00a0randomized clinical trial. JAMA Ophthalmol. 2021;139:725\u201333.","journal-title":"JAMA Ophthalmol"},{"issue":"19","key":"2691_CR39","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. 2016;375(19):1834\u201344.","journal-title":"NEJM."},{"issue":"10193","key":"2691_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et\u00a0al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a\u00a0double-blind, randomised placebocontrolled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"key":"2691_CR41","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempicrybelsus-wegovy."},{"issue":"7","key":"2691_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","volume":"143","author":"R Shor","year":"2025","unstructured":"Shor\u00a0R, et\u00a0al. Glucagon-Like Peptide\u20111 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2025;143(7):587\u201394.","journal-title":"JAMA Ophthalmol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02691-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:53Z","timestamp":1779315413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":42,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02691-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Pollreisz erh\u00e4lt ein Beraterhonorar von den Firmen Bayer, Novartis, Roche und AbbVie. B.\u00a0Gerendas erh\u00e4lt ein Beraterhonorar von den Firmen Bayer, Novartis und Roche sowie Forschungssupport von Digital Diagnostics. S.\u00a0Sacu erh\u00e4lt ein Beraterhonorar von den Firmen Bayer, Novartis und Roche. V.\u00a0Gasser-Steiner, S.\u00a0Mennel, S.\u00a0Radda, U.\u00a0Stolba und A.\u00a0Wedrich geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}